
    
      This Extension study is a 48-week treatment study, with a safety follow-up period of 12
      weeks. This study will evaluate the safety and tolerability of iscalimab at two dose levels
      in patients with Sj√∂gren's Syndrome, who must have participated in the TWINSS core study,
      CCFZ533B2201 (NCT03905525) and must have completed the entire treatment period up to Week 48
      and the follow-up period up to Week 60.

      Study treatment will be administered as bi-weekly subcutaneous injections (Q2W s.c.) via
      prefilled syringes (PFS).
    
  